Related Experiment Video
Updated: Oct 19, 2026
Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals
Published on: March 30, 2017
Influence of spacer device on drug delivery to young children with asthma
1Department of Paediatrics, Kolding Hospital, Denmark.
Insights
Spacer device volume is less critical for budesonide delivery in infants (10-25 months) than previously thought. Smaller spacers (under 750 ml) effectively deliver medication when used with a facemask.
Area of Science:
- Pediatric Pulmonology
- Respiratory Drug Delivery
- Pharmacokinetics
Background:
- Inhaled corticosteroids like budesonide are crucial for managing pediatric asthma.
- Spacer devices improve medication delivery to the lungs, but optimal device characteristics for infants are debated.
- Budesonide delivery varies significantly between different inhaler devices.
Purpose of the Study:
- To compare the delivered budesonide dose from three different spacer devices in infants aged 10-25 months.
- To assess the impact of spacer volume on budesonide delivery in young children.
- To evaluate the relationship between minute ventilation and medication delivery efficiency.
Main Methods:
- A randomized crossover study involving 20 children (10-25 months) receiving budesonide (200 mcg) via three spacers (Nebuhaler, Aerochamber, Babyspacer) with facemasks.
- Budesonide dose deposited on a filter was measured to determine delivery efficiency.
- Children's minute ventilation was recorded during a 30-second inhalation period.
Main Results:
- The Aerochamber (140 ml) delivered significantly less budesonide (39.4 mcg) compared to the Nebuhaler (53.5 mcg) and Babyspacer (55.5 mcg).
- All spacers were effectively emptied within 30 seconds by the children's minute ventilation (mean 5.0 L/min).
- Spacer volume did not appear to be the primary determinant of budesonide delivery in this age group.
Conclusions:
- Spacer volume is less critical for budesonide delivery in infants aged 10-25 months, provided volumes under 750 ml are used.
- Effective medication delivery is achievable with various spacer sizes when used with facemasks and appropriate breathing patterns.
- Further research may explore other factors influencing inhaled corticosteroid efficacy in infants.
Abstract:
The budesonide dose delivered to the patient from three different spacer devices (Nebuhaler = 750 ml, Aerochamber = 140 ml, and Babyspacer = 260 ml) was assessed by measuring the budesonide dose deposited on a filter inserted between the spacer outlet and the mouth of the patient. Twenty children aged 10-25 months were given a single dose of 200 micrograms budesonide from each spacer device in a randomised crossover study. All spacers had a facemask attached and a one way valve system. The children breathed through the inhalation system for 30 seconds. Furthermore, the minute ventilation of the children through a tightly fitting facemask was measured. The filter dose of budesonide was significantly lower after Aerochamber treatment (39.4 micrograms, range 19-67 micrograms) than after Nebuhaler (53.5 micrograms, range 34-88 micrograms) and Babyspacer (55.5 micrograms, range 39-76 micrograms) treatment. The minute ventilation of the children varied from 1.4 l/min to 7.0 l/min (mean 5.0 l/min). This was sufficient to empty all spacers within the 30 seconds of inhalation. It is concluded that spacer volume does not seem to be so important for children aged 10-25 months as long as spacers with a volume lower than 750 ml are used.
Related Concept Videos
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:23Inhaled Medications